Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash & Equivalents (2022 - 2025)

Cellebrite DI has reported Cash & Equivalents over the past 4 years, most recently at $124.5 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $124.5 million for Q4 2025, down 35.06% from a year ago — trailing twelve months through Dec 2025 was $124.5 million (down 35.06% YoY), and the annual figure for FY2025 was $124.5 million, down 35.06%.
  • Cash & Equivalents for Q4 2025 was $124.5 million at Cellebrite DI, down from $191.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CLBT hit a ceiling of $191.7 million in Q4 2024 and a floor of $87.6 million in Q4 2022.
  • Median Cash & Equivalents over the past 4 years was $157.0 million (2023), compared with a mean of $148.3 million.
  • Biggest five-year swings in Cash & Equivalents: surged 116.23% in 2023 and later crashed 35.06% in 2025.
  • Cellebrite DI's Cash & Equivalents stood at $87.6 million in 2022, then surged by 116.23% to $189.5 million in 2023, then rose by 1.13% to $191.7 million in 2024, then crashed by 35.06% to $124.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $124.5 million (Q4 2025), $191.7 million (Q4 2024), and $189.5 million (Q4 2023) per Business Quant data.